Costco's Stock Slips Despite Fertility Treatment Partnership Launch Traded 74th in $1.21 Billion Volume

Market Snapshot

Costco Wholesale (COST) closed March 17, 2026, with a 0.56% decline, trading at $X.XX per share. The stock saw a volume of $1.21 billion in transactions, ranking 74th in market activity for the day. Despite the launch of a new fertility treatment partnership, the share price moved lower, reflecting mixed market sentiment or broader sector pressures. The decline came as the company announced a program offering up to 80% discounts on fertility drugs, yet the stock’s performance suggests investors may be evaluating long-term profitability or competitive dynamics in the healthcare sector.

Key Drivers

Costco’s partnership with Sesame and IVI RMA to provide discounted fertility treatments represents a strategic expansion into the healthcare market. The collaboration aims to reduce out-of-pocket costs for members by offering exclusive pricing on fertility medications like Follistim, which can cost thousands of dollars per cycle. By fulfilling these prescriptions through its pharmacy network, Costco positions itself as a one-stop solution for members, combining affordability with coordinated care. The program includes telehealth appointments, diagnostic support, and referrals to IVI RMA for specialized treatments such as in vitro fertilization (IVF). This move aligns with broader consumer demand for cost transparency in healthcare and could enhance Costco’s value proposition beyond traditional retail offerings.

The 80% discount on fertility drugs is a critical differentiator in a market where out-of-pocket expenses often deter patients. For example, a single 650 IU cartridge of Follistim, a key medication in fertility treatments, typically costs around $1,268. By reducing this to approximately $253 per unit, Costco addresses a significant financial barrier for patients. The partnership also includes negotiated discounts for specialty care through IVI RMA, potentially lowering the total cost of IVF cycles, which can range from $12,000 to $25,000. These savings are particularly impactful in a demographic context where the U.S. fertility rate has declined to 53.8 births per 1,000 women aged 15–44, according to CDC data.

The initiative is framed as a response to regulatory developments, including President Trump’s 2025 executive order to expand access to IVF. The policy emphasizes reducing out-of-pocket costs and increasing tax deductions for newborn-related expenses, aligning with Costco’s mission to provide accessible, affordable solutions. IVI RMA CEO Lynn Mason explicitly cited the executive order as a catalyst for the partnership, underscoring the alignment between corporate strategy and national policy. This regulatory tailwind could amplify the program’s reach, particularly as the administration prioritizes family formation and healthcare affordability.

However, the stock’s decline on the day of the announcement suggests investors may be weighing potential challenges. While the program enhances member value, it could also compress profit margins in the pharmacy segment, which contributes significantly to Costco’s revenue. Additionally, the long-term sustainability of such discounts depends on the volume of members utilizing the services and the associated costs of care coordination. The market may be factoring in uncertainties around adoption rates or the financial viability of integrating healthcare services into a retail model.

Broader demographic trends further contextualize the partnership. With one in six people globally affected by infertility, per WHO estimates, demand for affordable solutions is rising. Costco’s entry into this market not only diversifies its offerings but also taps into a growing sector projected to expand as fertility treatments become more mainstream. The collaboration reflects a strategic pivot toward healthcare innovation, leveraging Costco’s existing infrastructure and member base to address a critical unmet need.

In summary, the partnership with Sesame and IVI RMA is a bold expansion for Costco, addressing both financial and logistical barriers to fertility care. While the stock’s short-term performance may reflect caution around profitability, the long-term potential of this initiative could position Costco as a key player in the evolving healthcare landscape. The success of the program will hinge on its ability to balance affordability with operational efficiency, all while navigating regulatory and market dynamics in a highly competitive sector.